Opinion on Pharmaceuticals and Healthcare in Italy

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Wyeth: positive Aprela results bode well for planned portfolio strategy

Wyeth has announced new positive Phase III data for its menopause treatment Aprela. The potential blockbuster is well positioned to provide a unique approach to the treatment of menopausal symptoms in women at risk of developing osteoporosis, and assuming regulatory hurdles can be overcome, Aprela will help further maintain Wyeth's position as a leading women's health player.

Published By Datamonitor
29 Jul 2009
ResearchWire
ResearchWire

Vinka alkaloids: market to fall 17% by 2007

Published By Datamonitor
16 May 2001
ResearchWire
ResearchWire

Vascular dementia: drug sales will rapidly proliferate

Published By Datamonitor
03 Apr 2002
ResearchWire
ResearchWire

Traumatic brain injuries: numbers will rise in US, fall in Germany and Italy

Published By Datamonitor
13 Nov 2001
CommentWire
CommentWire

Teva: increasing penetration in southern Europe

Generics giant Teva [TEVA] has agreed to acquire Italian generics company Dorom from Pfizer for $80 million, becoming the largest generics company in Italy. Over the longer term, continued geographical expansion will counteract Teva's recent share price drop and reduce the company's dependence on key branded products like Copaxone.

Published By Datamonitor
19 Aug 2004
CommentWire
CommentWire

Targacept: potential shift in research focus for ADHD candidate

Targacept's investigational neuronal nicotinic receptor agonist has failed to meet its primary endpoint in a Phase II trial in adults with attention deficit hyperactivity disorder. Datamonitor expects that future development focus for TC-5619 will shift towards schizophrenia, in view of Phase II data demonstrating efficacy in the treatment of cognitive dysfunction associated with the condition.

Published By Datamonitor
25 Mar 2011
Expert View
Expert View

Significant changes in store for growing HIV market

Worth $8 billion in 2006, the HIV market is expected undergo significant changes as it expands to an estimated $11.5 billion in 2016. Patent expiries on key drugs and product launches in new and existing classes are set to reshape the HIV treatment paradigm. One player set to lose out as its ageing HIV portfolio loses its patent protection is the current market leader, GlaxoSmithKline.

Published By Datamonitor
04 Oct 2007
CommentWire
CommentWire

Shire Pharmaceuticals: transatlantic growth spurt

Published By Datamonitor
11 Dec 2000
ResearchWire
ResearchWire

Schizophrenia: suffered by 1.3% of world population

Published By Datamonitor
27 Jun 2001
CommentWire
CommentWire

Schering-Plough/Centocor: wider Remicade indication

Published By Datamonitor
06 Feb 2001

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

No help is available.